The multi-award-winning trademarked brand of beta-caryophyllene will form a key part of experimental recovery protocol

With reports from improved energy and mental clarity, to dramatic recovery, Cannanda CB2 oil has been selected by Remission Biome as a therapeutic tool for ME/CFS & long COVID

VANCOUVER, BC, November 2, 2023 /3DMC Press/ — Cannanda, a pioneer in botanical terpene solutions, is excited to announce a significant milestone in the ongoing quest to bring relief to individuals suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Long COVID, and related conditions like fibromyalgia. Cannanda's proprietary and trademarked Cannanda CB2 oil has been selected to be a part of the largest patient-led self-experiment protocol ever run—organized and executed by, a company founded by two passionate PhD researchers, Tess Falor and Tamara Romanuk. These dedicated individuals each independently experienced dramatic and sudden remission from ME/CFS through self-experimentation. They found each other on social media in the fall of 2022 and created Remission Biome in January 2023 to investigate how to recreate these remission events and measure as many biomarkers as possible. Understanding how these remission events occur and why, will hopefully offer a glimmer of hope to the many thousands who endure these debilitating conditions.

Cannanda CB2 oil is a unique blend of terpenes, with beta-caryophyllene as its featured component. The oil is recognized for its outstanding safety profile, setting it apart from alternatives such as copaiba essential oil. Unlike copaiba (a natural source of beta-caryophyllene), Cannanda CB2 oil is created using only 100% Generally Recognized As Safe (GRAS) status ingredients, free from the concerning hepatotoxic diterpenes naturally found in copaiba.

Beta-caryophyllene is a natural compound and one of the major components of essential oils extracted from various spices, such as black pepper (Piper nigrum L.), rosemary (Rosmarinus officinalis), basil (Ocimum spp.), thyme (Thymus vulgaris), sage (Salvia officinalis), and cloves (Syzygium aromaticum). This plant compound is approved as a flavour enhancer by the US Food and Drug Administration (FDA), the European Food Safety Authority (EFSA), UK’s Food Standards Agency (FSA), and Health Canada.

Where it gets exciting is that beta-caryophyllene is a “selective CB2 receptor agonist,” meaning it can activate one of the main cannabinoid receptors in the body—the CB2 receptor—without causing the intoxication that’s associated with the activation of CB1 receptors. The activation of CB2 receptors has been shown to elicit a number of potential benefits as discussed in the 2019 peer-reviewed journal article titled, β-Caryophyllene: A Sesquiterpene with Countless Biological Properties.

What makes Cannanda CB2 oil even more remarkable is its superior efficacy. This breakthrough was achieved by following the principles of botanical medicine, where—unlike single isolated compounds (e.g., pure beta-caryophyllene)—complementary components enhance the absorption and effectiveness of therapeutic ingredients. As a result, Cannanda CB2 oil has already received testimonials from numerous individuals as a successful treatment for ME/CFS, long COVID, and fibromyalgia.

Another benefit of beta-caryophyllene is that it has GRAS status (Generally Recognized as Safe), which is a US-based food safety designation, and is not known to have adverse drug-interactions as described in a recent scientific investigation into the topic titled, Sesquiterpenes Are Agonists of the Pregnane X Receptor but Do Not Induce the Expression of Phase I Drug-Metabolizing Enzymes in the Human Liver.

This is an important point since the multi-pronged experimental protocol involves the use of various other therapeutics, including antibiotics, in an attempt to understand why Romanuk and Falor experienced their remission event. All done to understand what it might take to reproduce those remission events and support recovery.

In this exciting development, Cannanda’s proprietary beta-caryophyllene products, known as the trademarked Cannanda CB2, was selected for its high-quality reputation, which includes clean ingredients and formulation, cGMP-manufacturing, and third-party testing. It is also widely available making it simple for many individuals to access the same consistent beta-caryophyllene products in Canada, Australia, US, UK, and the EU.

“We are proud to be a part of this experimental protocol for ME/CFS and long COVID, which, by the way, will be conducted with full independence. Cannanda will have no influence over the protocol, results, analysis, or reporting,” said Dr. Lee Know, Cannanda’s co-founder and Managing Director. The company is committed to the highest standards of scientific integrity, ensuring a fair and unbiased evaluation of their products.

Based on previous experiences and extensive feedback from satisfied users, Cannanda claims an estimated success rate of 60-70%. This means that, on average, two out of three individuals using the products report experiencing significant benefits (by contrast it’s commonly thought that most therapeutics, whether pharmaceuticals or other natural health products, have a 30-50% success rate). With such promising results, Cannanda CB2 oil is poised to provide a much-needed solution for thousands of people living with ME/CFS, long COVID, and fibromyalgia.

Other aspects of the experimental protocol include extensive testing of biomarkers, modification of an individual’s microbiome through the use of specific antibiotics and probiotic strains, and other health supplements.

As the inventor of CB2 oil, Cannanda is committed to the well-being of those it serves and strives to support groundbreaking research. The company eagerly anticipates that the results of this clinical study will align with the experiences of many individuals who have already found relief through Cannanda CB2 oil.

Cannanda is profoundly grateful to be selected as a part of this patient-led initiative and collaborate with Remission Biome in their mission to better understand these chronic health conditions that impact countless individuals.

For media inquiries or further information, please visit